Source: Annual Congress 2012 - New insights in pneumology - ERS inter-Assemblies late-breaking abstracts
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Timmer, K. Kutz, G. Schlüter, F. Seitz, U. Wannenwetsch, J. Kuhlmann, M. Stauss-Grabo, A. Zensi, O. Schmidt, G. Breipohl, H. Renz, J. Bille, U. Homburg, H. Garn (Marburg, Mannheim, Wuppertal, Niederdorfelden, Hilden, Germany; Basel, Switzerland). LATE-BREAKING ABSTRACT: Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a first-in man study in healthy subjects. Eur Respir J 2012; 40: Suppl. 56, 2738

Member's Comments

No comment yet.

Related content which might interest you: Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006 Multiple-dose study of AMG 853 in healthy adults: Safety and pharmacokinetics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010 Safety and tolerability of single doses of AZD5069 in healthy volunteers Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 Safety, pharmacokinetics and pharmacodynamics of BI 1323495 in healthy males Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Multiple-dose study of AMG 317 in adults with asthma: pharmacokinetics and safety Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009 Single-dose, first-in-human study of AMG 317: safety and pharmacokinetics in healthy and asthmatic adults Source: Annual Congress 2008 - New treatments for asthma Year: 2008 LATE-BREAKING ABSTRACT: Safety, pharmacokinetic and pharmacodynamic profile of RV1162, a narrow spectrum kinase inhibitor, in healthy subjects and COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019 Dry powder inhaled ribavirin in healthy volunteers:  safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017 Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012 Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 LATE-BREAKING ABSTRACT: Acute effect of e-cigarette on pulmonary function in healthy subjects and smokers Source: Annual Congress 2012 - Tobacco dependence and respiratory disease Year: 2012 A comparative study on systemic pharmacodynamic effects of two HFA formulations of salmeterol xinafoate, in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004